ERBB2 and triple-negative breast carcinoma: The choice of a therapeutic scheme, suggested by Clinical Practise Guidelines, is related to the existence of BC molecular/immunohistochemical (IHC) subtypes: Luminal A, Luminal B, human epidermal growth factor receptor 2 (HER2)/neu enriched, basal-like and triple-negative breast cancer (TNBC) (1).